1. Thienopyrimidine-based P2Y12 platelet aggregation inhibitors
- Author
-
Hayat K. Rahman, Tenbrink Ruth E, Barbara A. Schweitzer, Rita M. Huff, Steven W. Kortum, Gopichand Yalamanchili, Rhonda M. Lachance, and Ennis Michael D
- Subjects
Platelet Aggregation ,medicine.drug_class ,Clinical Biochemistry ,Pharmaceutical Science ,Carboxamide ,Plasma protein binding ,Biochemistry ,Chemical synthesis ,Structure-Activity Relationship ,P2Y12 ,Fibrinolytic Agents ,Drug Discovery ,Purinergic P2 Receptor Antagonists ,medicine ,Humans ,Structure–activity relationship ,Platelet ,Molecular Biology ,Receptors, Purinergic P2 ,Chemistry ,Organic Chemistry ,Receptors, Purinergic P2Y12 ,In vitro ,Pyrimidines ,Molecular Medicine ,Platelet aggregation inhibitor ,Platelet Aggregation Inhibitors ,Protein Binding - Abstract
Herein we describe the design and synthesis of a novel series of potent thienopyrimidine P2Y12 inhibitors and the negative impact protein binding has on the inhibition of platelet aggregation.
- Published
- 2009